Find Clinical Trials

September 21, 2022 in Genitourinary (GU)

A032101

A phase 2 trial of ADT interruption in patients responding exceptionally to AR pathway inhibitor in metastatic hormone-sensitive prostate cancer (MHSPC): A-DREAM NCT #05241860
Read More
August 26, 2022 in Genitourinary (GU)

EA8191

EA8191: Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE) (NCT04423211)
Read More
July 11, 2022 in Genitourinary (GU)

WF1802

​WF1802: Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW) ​
Read More
July 11, 2022 in Genitourinary (GU), Melanoma

SGNLVA-005

SGNLVA-005: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Read More
July 11, 2022 in Genitourinary (GU)

S1937

S1937: A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible…
Read More
July 11, 2022 in Genitourinary (GU)

S1931

S1931: PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL) (Study SWOG 1931) (NCT#0451059)
Read More
July 11, 2022 in Genitourinary (GU)

S1806

S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Read More
July 11, 2022 in Genitourinary (GU)

S1802

Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer).
Read More
June 30, 2022 in Genitourinary (GU)

GU011

GU011: A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN) (NCT# 05053152)
Read More
June 30, 2022 in Genitourinary (GU)

GU010

GU010: Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) (NCT#05050084)
Read More
June 30, 2022 in Genitourinary (GU)

GU009

GU009: Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT*) (NCT#04513717)…
Read More
June 30, 2022 in Genitourinary (GU)

GU008

GU008: Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (NCT #04134260)
Read More
June 30, 2022 in Genitourinary (GU)

EA8192

EA8192: A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Read More
June 30, 2022 in Genitourinary (GU)

EA8185

EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (durvalumab) in Clinical Stage 3, node PosItive BladdeR CancEr (INSPIRE) (NCT04216290)
Read More
June 30, 2022 in Genitourinary (GU)

EA8183

EA8183: A Phase III Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic…
Read More
June 30, 2022 in Genitourinary (GU)

AREN1721

Axitinib and Nivolumab in Treating Participants With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma
Read More
June 30, 2022 in Genitourinary (GU)

A032002

A032002: Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
Read More
June 30, 2022 in Genitourinary (GU)

A032001

A032001: Testing the addition of the anti-cancer drug, cabozantinib, to the usual immunotherapy treatment, avelumab, in patients with metastatic urothelial cancer
Read More
June 30, 2022 in Genitourinary (GU)

A031902

A031902 (CASPAR): A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-resistant Prostate Cancer NCT: 04455750
Read More
June 30, 2022 in Genitourinary (GU)

A031901

A031901: Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Read More
June 30, 2022 in Genitourinary (GU)

A031801

A031801: A Phase II Randomized Trial of Radium-223 dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCaL)
Read More
June 30, 2022 in Genitourinary (GU)

A031704

A031704: PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab in metastatic untreated REnal Cell CancEr (NCT03793166)
Read More
June 29, 2022 in Genitourinary (GU)

A031702

A031702: A phase II study of Ipilimumab, CabOzantinib, and NIvolumab in rare genitourinary Cancers (ICONIC) (NCT03866382)
Read More
June 29, 2022 in Genitourinary (GU)

A031701

Gemcitabine Hydrochloride and Cisplatin in Treating Participants With Invasive Bladder Urothelial Cancer
Read More